Direkt zum Inhalt
Merck

M7920

Minoxidilsulfat -sulfat (Salz)

K+ channel opener, powder

Synonym(e):

U-58838

Anmelden zur Ansicht der Organisations- und Vertragspreise.

Größe auswählen

1 MG

€ 61,90

5 MG

€ 168,00

€ 61,90


Warenkorb auf Verfügbarkeit prüfen

Großbestellung anfragen

Über diesen Artikel

Empirische Formel (Hill-System):
C9H15N5O4S
CAS-Nummer:
Molekulargewicht:
289.31
UNSPSC Code:
12352107
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Form:
powder
Quality level:

Fortfahren mit

Technischer Dienst
Benötigen Sie Hilfe? Unser Team von erfahrenen Wissenschaftlern ist für Sie da.
Unterstützung erhalten

Produktname

Minoxidilsulfat -sulfat (Salz),

SMILES string

Nc1cc(nc(N)[n+]1OS([O-])(=O)=O)N2CCCCC2

InChI

1S/C9H15N5O4S/c10-7-6-8(13-4-2-1-3-5-13)12-9(11)14(7)18-19(15,16)17/h6H,1-5H2,(H4,10,11,12,15,16,17)

InChI key

OEOLOEUAGSPDLT-UHFFFAOYSA-N

form

powder

originator

Johnson & Johnson

storage temp.

−20°C

Quality Level

Verwandte Kategorien

Ähnliche Artikel vergleichen

Vollständigen Vergleich anzeigen

Unterschiede anzeigen

1 of 4

Dieser Artikel
566405P1537D8174
form

powder

form

solid

form

powder

form

solution

Quality Level

200

Quality Level

100

Quality Level

200

Quality Level

200

storage temp.

−20°C

storage temp.

2-8°C

storage temp.

−20°C

storage temp.

−20°C

originator

Johnson & Johnson

originator

-

originator

-

originator

-

Application

Minoxidil sulfate (MXS) has been used as a drug agent to study its effects on alopecia in corticotropin-releasing factor over-expressing (CRF-OE) mice.[1] It has also been used as a positive control in an assay for the culturing of rat vibrissa follicles.[2]

Biochem/physiol Actions

Minoxidil sulfate (MXS) is an endogenous derivative of minoxidil. It possesses greater aqueous solubility and is a potent vasodilator. MXS has the potential to treat androgenic alopecia or male baldness.[3]

Features and Benefits

This compound was developed by Johnson & Johnson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Other Notes

Active metabolite of minoxidil.

pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Lagerklasse

11 - Combustible Solids

wgk

WGK 3

ppe

dust mask type N95 (US), Eyeshields, Gloves


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

K D Meisheri et al.
The Journal of pharmacology and experimental therapeutics, 266(2), 655-665 (1993-08-01)
This study describes the in vitro and in vivo characteristics of a guanidine 4-morpholinecarboximidine-N-1-adamantyl-N'-cyclohexyl-hydroc hloride (U-37883A), as an antagonist of vascular ATP-sensitive K+ channels (KATP). In isolated rabbit mesenteric artery, the antagonistic effects of U-37883A (0.5-5 microM) were studied against
Pharmacological effects of drug conjugates: is morphine 6-glucuronide an exception?
G J Mulder
Trends in pharmacological sciences, 13(8), 302-304 (1992-08-01)
Michael J Shackcloth et al.
European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 34(4), 839-844 (2008-08-06)
Vasodilator strategies used to treat bypass grafts in the operating theatre, such as nitrates, phosphodiesterase inhibitors and calcium channel antagonists have a broad but short-lived effect against a variety of vasoconstrictor stimuli. Treatments that react irreversibly with proteins modulating vasoconstriction
K S Atwal
Journal of cardiovascular pharmacology, 24 Suppl 4, S12-S17 (1994-01-01)
KATP openers are recognized as having a therapeutic potential for the treatment of various cardiovascular and noncardiovascular diseases. However, the first-generation agents open KATP in a variety of tissues that limit their potential clinical utility. This review describes our studies
Nagendra S Ningaraj et al.
Cancer research, 63(24), 8899-8911 (2003-12-26)
Brain tumor microvessels/capillaries limit drug delivery to tumors by forming a blood-brain tumor barrier (BTB). The BTB overexpresses ATP-sensitive potassium (K(ATP)) channels that are barely detectable in normal brain capillaries, and which were targeted for BTB permeability modulation. In a

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung